For example, older populations with established CVD for which SGLT2i or GLP1-RA medicines have multiple benefits in reducing both the risk of CVD events and chronic kidney disease while reducing other risk factors such as body fat mass, blood pressure and improving lipid profiles [1]. This evidence concerns the gene GLP1R and chronic kidney disease.